Compare Dishman Pharma with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs NEULAND LABS - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA NEULAND LABS DISHMAN PHARMA/
NEULAND LABS
 
P/E (TTM) x 25.1 71.5 35.1% View Chart
P/BV x 3.3 2.5 131.3% View Chart
Dividend Yield % 0.7 0.1 468.7%  

Financials

 DISHMAN PHARMA   NEULAND LABS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
NEULAND LABS
Mar-20
DISHMAN PHARMA/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs374754 49.7%   
Low Rs129247 52.1%   
Sales per share (Unadj.) Rs197.8594.5 33.3%  
Earnings per share (Unadj.) Rs21.212.6 167.9%  
Cash flow per share (Unadj.) Rs34.737.0 93.8%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.4 198.9%  
Book value per share (Unadj.) Rs179.9553.4 32.5%  
Shares outstanding (eoy) m80.6912.83 628.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.8 151.1%   
Avg P/E ratio x11.939.6 30.0%  
P/CF ratio (eoy) x7.213.5 53.6%  
Price / Book Value ratio x1.40.9 154.7%  
Dividend payout %9.415.8 59.6%   
Avg Mkt Cap Rs m20,3066,421 316.2%   
No. of employees `0000.81.3 64.7%   
Total wages/salary Rs m5,3551,236 433.4%   
Avg. sales/employee Rs Th19,252.75,949.4 323.6%   
Avg. wages/employee Rs Th6,459.5963.8 670.2%   
Avg. net profit/employee Rs Th2,064.1126.4 1,632.6%   
INCOME DATA
Net Sales Rs m15,9617,627 209.3%  
Other income Rs m26539 683.1%   
Total revenues Rs m16,2267,666 211.7%   
Gross profit Rs m4,1031,019 402.7%  
Depreciation Rs m1,091313 348.7%   
Interest Rs m944216 437.8%   
Profit before tax Rs m2,334529 441.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624367 169.9%   
Profit after tax Rs m1,711162 1,055.7%  
Gross profit margin %25.713.4 192.4%  
Effective tax rate %26.769.4 38.5%   
Net profit margin %10.72.1 504.5%  
BALANCE SHEET DATA
Current assets Rs m11,0185,152 213.9%   
Current liabilities Rs m9,5173,576 266.1%   
Net working cap to sales %9.420.7 45.5%  
Current ratio x1.21.4 80.4%  
Inventory Days Days110105 105.2%  
Debtors Days Days3591 38.3%  
Net fixed assets Rs m16,3043,969 410.8%   
Share capital Rs m161129 125.1%   
"Free" reserves Rs m12,9076,971 185.2%   
Net worth Rs m14,5167,100 204.5%   
Long term debt Rs m4,189774 541.5%   
Total assets Rs m29,80512,310 242.1%  
Interest coverage x3.53.5 100.5%   
Debt to equity ratio x0.30.1 264.8%  
Sales to assets ratio x0.50.6 86.4%   
Return on assets %8.93.1 290.3%  
Return on equity %11.82.3 516.4%  
Return on capital %17.59.5 185.3%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,9525,187 95.5%   
Fx outflow Rs m6971,593 43.7%   
Net fx Rs m4,2553,594 118.4%   
CASH FLOW
From Operations Rs m2,786573 485.9%  
From Investments Rs m-1,529-487 314.1%  
From Financial Activity Rs m-941-55 1,717.3%  
Net Cashflow Rs m31633 970.6%  

Share Holding

Indian Promoters % 61.4 36.3 169.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 63.7 5.8%  
FIIs % 12.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 63.7 34.7%  
Shareholders   46,261 12,705 364.1%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  ALEMBIC  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indigo Paints IPO, December Quarter Results, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended at record-high levels yesterday with Nifty ending above 14,600-mark.

Related Views on News

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS